Reneo achieves target enrollment in Phase 2b STRIDE trial of mavodelpar; topline Q4 2023

OnKure Therapeutics, Inc.

Target enrollment reached in global STRIDE study for mavodelpar in adult PMM patients.
STRIDE AHEAD long-term safety trial amended to enroll PMM due to mtDNA and nuclear DNA defects.
Topline data from STRIDE expected in Q4 2023; marketing applications planned for 2024.
STRIDE is a randomized, double-blind, placebo-controlled Phase 2b trial of 100 mg mavodelpar daily.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.